• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

    11/26/24 8:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SGMT alert in real time by email

    SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 10 a.m. EST in New York City, New York.

    A webcast of the presentation will be available in the Investors & Media section of Sagimet's website at www.sagimet.com, with an archived replay available for 90 days following the live event.

    About Sagimet Biosciences 

    Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit www.sagimet.com.

    Contact:

    Joyce Allaire 

    LifeSci Advisors 

    [email protected]

    Source: Sagimet Biosciences Inc.



    Primary Logo

    Get the next $SGMT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What event will Sagimet Biosciences Inc. be presenting at, and when?

      Sagimet Biosciences is presenting at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024.

    • What is Sagimet's lead drug candidate, and what condition is it targeting?

      Denifanstat is an oral, once-daily pill and selective FASN inhibitor being developed for the treatment of metabolic dysfunction associated steatohepatitis (MASH).

    • What significant FDA designation has the lead drug candidate, denifanstat, received?

      Denifanstat has received Breakthrough Therapy designation from the FDA for treating non-cirrhotic MASH with moderate to advanced liver fibrosis.

    • What clinical trial related to denifanstat has been completed, and what were the results?

      The FASCINATE-2 clinical trial of denifanstat was successfully completed, demonstrating positive results.

    • How can investors access the presentation by Sagimet Biosciences, and for how long will the replay be available?

      A webcast of the presentation will be accessible in the Investors & Media section of Sagimet's website, with a replay available for 90 days post-event.

    Recent Analyst Ratings for
    $SGMT

    DatePrice TargetRatingAnalyst
    12/6/2024$30.00Outperform
    Oppenheimer
    11/12/2024$12.00Buy
    UBS
    6/28/2024$23.00 → $6.00Buy → Neutral
    Goldman
    5/2/2024$32.00Buy
    H.C. Wainwright
    3/25/2024$26.00Outperform
    Leerink Partners
    8/8/2023Outperform
    TD Cowen
    8/8/2023$67.00Overweight
    Piper Sandler
    8/8/2023$33.00Buy
    Goldman
    More analyst ratings